| abstract |
Modified antibodies with improved pharmacokinetic properties are disclosed. The antibodies bind to one or more human integrin receptors selected from the group consisting of GPIIb/IIIa, αvβ3 and Mac-1, and comprise one to about six organic moieties which are covalently bonded to specific sites on the antibodies. The organic moieties can each independently be a hydrophilic polymeric group, a fatty acid group, a fatty acid ester group, a lipid group or a phospholipid group. Also disclosed is a method of treating a human with a disease or disorder in which cells expressing GPIIb/IIIa,αvβ3 and/or Mac-1 play a pathophysiological role. The method comprises administering an effective amount of one or more antibodies of the invention to a human in need thereof. |